Brimonidine topical gel 0.33% (Mirvaso, Galderma Laboratories) has been approved by the FDA for facial redness resulting from rosacea in adults aged 18 years or older In clinical testing, the alpha 2 adrenergic agonist brimonidine topical gel yielded significantly greater improvement in the facial redness of rosacea than vehicle gel, according to the company sponsor… Read More
